Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 5/20 | 0.32 |
| ▸ | PPARA | Q07869 | 8/20 | 0.32 |
| ▸ | PPARD | Q03181 | 5/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246371 | 0.90 | HDAC1 (0.35) | ANO1HDAC1MAOB | |
| SCHEMBL3244300 | 0.88 | MAPT (0.40) | PDK2ANO1PPARD | |
| SCHEMBL3238209 | 0.82 | PPARA (0.42) | PPARGPPARAHDAC1 | |
| SCHEMBL3241695 | 0.78 | ALOX5 (0.33) | — | |
| SCHEMBL3241611 | 0.78 | MAPT (0.38) | ANO1MAOB | |
| SCHEMBL7246421 | 0.76 | MAOB (0.44) | HDAC1MAOB | |
| SCHEMBL1592717 | 0.75 | ALDH1A1 (0.39) | PDK2 | |
| SCHEMBL6543994 | 0.74 | ESRRA (0.39) | — | |
| SCHEMBL6543598 | 0.74 | ESRRA (0.50) | — | |
| SCHEMBL27782504 | 0.73 | FFAR1 (0.39) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | PDK2 2752/4885ANO1 2441/4885PPARG 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.